The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refractory pediatric GvHD.
A double-blind RCT shows cord blood stem cells improved social cognition in children with autism. Here's what parents need to know about the latest research, safety data, and treatment process.
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.
Research shows MSC activity drops 40% by age 50. Learn what changes inside aging cells and three emerging therapies showing real results in 2026 clinical trials.
Медицинский обзор клинических испытаний МСК 2026 года: ключевые данные из ISCT Dublin, японского исследования III фазы по восстановлению мениска с помощью синовиальных МСК, данные по остеоартрозу, полученным при сравнении костного мозга и пуповинной ткани, а также механизмы действия митохондриальных внеклеточных везикул.
В нашей клинике в Бангкоке изучают, как терапия с использованием мезенхимальных стволовых клеток помогает пациентам с ХОБЛ легче дышать — уменьшая воспаление, активируя стволовые клетки легких и улучшая качество жизни.
Russian 
English 
Chinese 
French